Referral Centre VRCC reports that its first Small Animal Veterinary Education Conference Weekend in Kenya, held in November and supported by Merial, has been a great success. Over 30 East African vets from all over Kenya gathered at the elegant Leopard Beach Hotel, just south of Mombasa, to learn from some of the leading specialists in the UK.
The Kenyans, all with an interest in small animals, were a real cross section of the African profession. They ranged from prosperous vets with large practices in Nairobi to a young vet who'd undertaken a gruelling 7 hour bus ride accompanied by armed guards from his clinic on Lamu, near the Somali border.
A challenging 2 day programme had been devised by VRCC specialists including Dr Susan North, one of the most experienced and highly qualified veterinary oncologists in Europe and also a European Specialist in Internal Medicine. Also lecturing were VRCC's Head of Surgery, Henry L'Eplattenier and Merial's Dr Hein Hesse, an expert in pain management and parasite control. The weekend finished with a prolonged question and answer session with the enthusiastic delegates hungry to gain as much knowledge as possible from the visiting specialists before their long journey home.
Malcolm Holland at VRCC was delighted with the first time turn-out at the conference. He said: "The Conference Weekend was successful on so many fronts. The delegates had access to first-hand information not readily available to them - the last lecturing team visited over 20 years ago! They were able to interact with each other, form networks, and renew friendships.
"VRCC was not seeking any material gain, just fulfilling a desire to pass on some of our experience for the improved welfare of small animals in East Africa."
VRCC expects attendance to more than double now Kenyan vets know that commitments will be fulfilled. Specialists keen to participate in future events or companies with interests or ambitions in Kenya should contact Malcolm Holland at VRCC.
Vetoquinol has made changes to Zentonil®, its liver support range for dogs and cats.
New Zentonil® is the UK's FIRST palatable and divisible tablet range of S-adenosyl-methionine (SAMe) supplementation and now comes with the added benefit of choice: Zentonil® Advanced which contains pure SAMe plus silybin and Zentonil® Plus which contains pure SAMe only.
A patent pending microencapsulation technique protects the SAMe from the harmful effects of stomach acid, even when the tablet is split or chewed.
The ability to split the tablets makes administration more accurate and also makes the product more cost-effective for clients.
Vetoquinol's new Zentonil® formulations have proven SAMe bioavailability curves in a market where this particular type of data is often lacking
Simon Boulton, product manager said: "Our customers told us that they had difficulties associated with SAMe supplementation. We have listened to their comments and provided the solutions."
The new formulations will become available as wholesalers' Zentonil® stocks are depleted. If you wish to try new Zentonil® now, you can place an order for Zentonil® Advanced or Zentonil® Plus with your wholesaler.
For more information, please contact your local Vetoquinol sales representative or telephone the free practice support number - 0800 1698197.
Pooch & Mutt has 20x 40-day trials of its new joint & bone supplement, Mobile Bones Concentrate, to give away to veterinary professionals.
Guy Blaskey from Pooch & Mutt said: "At The London Vet Show vets and vet nurses told us that they loved the new Mobile Bones Concentrate because at just £9.99 per month it costs less than other joint supplements (whilst having the same high quality ingredients), it takes up a very small amount of shelf space and it doesn't involve the client having to either change their dog's food or stuff pills down their dog's throat."
In response to requests from vets and vet nurses to try the new joint supplement, Pooch & Mutt have set up a dedicated website at www.jointsupplementfordogs.com where you can apply from one of twenty 40 day trials.
Guy continued, "We did not want to simply send samples out to everyone. By setting up the site we can choose a variety of dogs from different breed and with different conditions to send a full 40-day trial to. We hope to get regular feedback from the vets, vet nurses and dog owners involved in the trial and publish it on http://www.jointsupplementfordogs.com/ for everyone else to see."
The trials are available to all veterinary professionals and can be for their own dogs, or dogs belonging to their clients.
The President of the Veterinary Benevolent Fund (VBF) Dr Lydia Brown has been awarded an MBE in the Queen's New Years Honours List, for services to the veterinary profession.
Lydia qualified as a veterinary surgeon from Liverpool and has spent most of her professional career in commerce. She was a member of Council of the Royal College of Veterinary Surgeons from 1991- 2007 and President in 1998-1999. During this period, she mobilised the veterinary profession to support the establishment of the Veterinary Surgeons Health Support Programme (VSHSP), which was launched in 1999 to help vets recover from addictive diseases and mental health problems. Since then the programme has helped some 300 vets and supported their families and colleagues in practice.
From 1993-1998 Lydia was a member of the Steering Committee of VetHelpline, a 24/7 telephone line for vets and their families, vet students and vet nurses who wish to discuss emotional, addictive or financial problems empathetically with someone who has experience of the profession. She became a Director of the VBF in 2005, when the Fund merged with VSHSP and VetHelpline under the umbrella of the VBF, and was elected President of the Fund in 2006.
Lydia said: "It gives me great pleasure to receive this award. The achievements of the VBF reflect the tireless work of many colleagues, who give their time unstintingly to help members of the profession less fortunate than themselves."
Harvey Locke, President of the British Veterinary Association, said: "This is a fitting award in recognition of Dr Brown's tremendous achievements. She is an eminent member of the veterinary profession who works tirelessly and compassionately to help others.
"The high prevalence of depression and suicide in the veterinary profession is well documented and Dr Brown has been instrumental in ensuring that help and support is available to help veterinary surgeons, veterinary students and veterinary nurses in need."
Lydia is active in a number of areas of the veterinary profession and is also a lay canon and member of chapter of Salisbury Cathedral, and a non-executive Director of the Salisbury NHS Foundation Trust Hospital.
On day one, Laura Playforth, IVC Evidensia’s Group Quality Improvement Director, will be looking at psychological safety and the adoption of a safety-critical culture in veterinary practice.
Sayaka Okushima from Pride Veterinary Referrals and Sarah Heath, IVC's Director of Sustainability, will be discussing the use of anaesthetic gases and ways to reduce them.
Other talks on day one will include: ‘Vets vs Nurses: Are we Blurring the Lines?’ and ‘The Criminal Underworld and Animal Welfare’.
On the second day, IVC referral clinicians will present lectures on various subjects, from handling emergency situations to mastering diagnostic testing equipment in first opinion practice.
David Owen, a Referral ECC Clinician at Vets Now in Manchester, will be talking about talking about emergency dyspnoea cases and how veterinary colleagues can cope with challenging situations efficiently.
Frances Bird, a European Specialist in Small Animal Surgery at Pride Veterinary Referrals, will be closing out the day with a discussion on treating respiratory disease from a surgeon’s perspective.
For the full programme, visit: https://london.vetshow.com/conference-programme?&filters.LOCATION=63903&searchgroup=ADD5CDE8-conference-programme-2023
The Committee has been named after the Supplementary Royal Charter 2015 which broadened the functions of the RCVS and allowed for a more flexible approach when dealing with complaints about professional conduct.
The Charter Case Committee can resolve cases where the conduct of a veterinary surgeon or nurse has fallen far below the level of conduct expected of them, but not so far as to warrant a full, public Disciplinary Committee hearing.
The Committee can deal with such cases without the need for a public hearing and can give veterinary surgeons or nurses either a confidential or a public warning about their future conduct.
A warning issued by the Charter Case Committee does not affect the individual’s registration status or their right to practise.
Eleanor Ferguson, RCVS Registrar, said: “The establishment of the Charter Case Committee plays a vitally important role in balancing our statutory role of upholding professional conduct standards and protecting animal health and welfare and public confidence in the professions, with our mission to become a compassionate regulator.
“The Charter Case Committee Protocol allows for the alternative resolution of certain cases where a veterinary surgeon or veterinary nurse has engaged in behaviour that amounts to serious professional misconduct or has been convicted of an offence, but where it is not in the public interest for the matter to be referred to a hearing of the Disciplinary Committee because it is at the lower end of seriousness.
“The type of cases we envisage being dealt with by the Committee are those where the Code has been breached but where there is no ongoing risk to animal welfare or public confidence, and where the level of insight and personal reflection regarding their conduct is such that it can be resolved without the need for an onerous, stressful and expensive Disciplinary Committee hearing.
"We estimate that the CCC will deal with around 20 such cases per year.
“The most serious cases of professional misconduct will, of course, continue to be referred to Disciplinary Committee hearings.”
https://www.rcvs.org.uk/who-we-are/committees/charter-case-committee.
The working group, which is led by Gudrun Ravetz, IVC's Group Chief Medical Officer, has been tasked with developing evidence-based, sustainable prescribing practices that protect animal health while safeguarding the planet.
The group comprises experts from within IVC Evidensia’s network who will collaborate with industry and academic partners including Vetoquinol, IDEXX, ESCCAP, and MSD Animal Health to deliver research, education, and practical tools for veterinary teams both inside and outside of IVC Evidensia practices.
Gudrun said: “We’re proud to be investing in this work and setting an example for the profession.
"Responsible parasiticide use is not just a clinical issue, it’s a sustainability imperative.”
Photo: www.depositphotos.com
The majority of posters, leaflets and other displays in veterinary practice waiting rooms are more effective at building ambience than increasing the turnover of the practice or selling a particular product or brand, according to a new survey carried out by veterinary marketing agency TMA.
The national survey of more than 100 veterinary practice managers found that:
TMA says it believes practices are missing out on a major marketing opportunity by not changing their displays more often, not being more selective about what is displayed, and not making the most of interactive or digital display technology.
Helen Cawthra, Managing Director of TMA believes that product manufacturers are also missing out on a major opportunity. Significantly less than half of all display and point-of-sale material in vets' waiting rooms is provided by suppliers. On average, 64% is sourced by the veterinary surgeons themselves.
Helen said: "Two thirds of respondents claim that they hardly get any materials from suppliers. The same number claim they would be more likely to put up more if they were provided with it.
"It is all very well building ambience and providing loyalty but in today's market, it is important that vets take hold of every opportunity to generate revenue in every way possible. Vets and the manufacturers are both missing out."
Douxo Care Auricular Lotion can be used for routine ear cleaning and removal of ear wax and as an ear cleaner prior to treatment in order to clean the ear canal of debris. Ceva says it is fast drying and pleasant to use and the lotion can also be adapted for the routine cleaning of skin folds and around the eyes.
Andrew Fullerton BVSc (Hons) MRCVS, Douxo product manager at Ceva Animal Health, said: “Following requests from dermatologists to launch this product in the UK, we are very excited to add Douxo Care Auricular Lotion to the UK Douxo range. It will provide a gentle yet effective and soothing option for dogs and cats needing regular ear cleaning and all under the Douxo brand we know and love.”
To support the launch of Douxo Care Auricular Lotion, the company is running a buy one, get one free offer (used once and up to a maximum of five units ie pay for five and receive five free of charge). For information on the offer, which runs until 31 October, contact cevauk@ceva.com, use the offer QR code or call 01494 781510 to request an order form or to process an order.
For more information, contact cevauk@ceva.com, call 01494 781510 or visit www.douxo.com/uk.
The company says the webinars will equip veterinary professionals with strategies to strengthen wellbeing both individually and for practice teams.
Lauren Hayes, Scientific and Regulatory Affairs Manager at Royal Canin, said: “Working within clinical veterinary practice can be hugely rewarding and enriching, but it cannot be ignored that our industry also has its challenges.
"Veterinary surgeons have a significantly higher risk of suicide compared to the general population and mental health issues around work life balance and compassion fatigue are widespread.
"Through our webinar series, we hope to encourage conversations around mental health and help provide advice directly from leading experts.”
The one-hour webinars will take place at 7pm every Wednesday throughout September.
https://vetportal.royalcanin.co.uk/news/new-veterinary-professional-health-webinar-series/
Dechra says Equisolon is the only registered oral prednisolone powder that alleviates the inflammation and clinical parameters associated with severe equine asthma, previously known as recurrent airway obstruction (RAO).
Equisolon Jar contains 180g of powder and comes with a measuring spoon.
One scoop is enough to treat 150kg bodyweight at a dose of 1mg/kg and therefore one jar can treat a 600kg horse for 10 days.
Equisolon was previously available as a box of 10 x 9g pre-measured sachets with one sachet sufficient to treat a 300kg horse and a box contained enough sachets to treat a 600g horse for five days.
Alana McGlade, national sales manager at Dechra said: “The addition of Equisolon Jar to the Equisolon range provides vets with the flexibility to choose between a jar featuring a convenient measuring spoon and a box of easy to dose pre-measured sachets
www.dechra.co.uk/products/horse/prescription
The group is hoping to raise more than £5,000 for the hospital by donating £1 for every pet vaccinated at its West Derby, Gateacre, St Helens and Widnes practices over the next four months.
Sarah Kirkman MRCVS, from White Cross Vets in Gateacre, said: "It’s our job to care for pets, but we also really care about the communities in which we operate, and we have a real affinity with the hospital. This partnership means we’re protecting pets, by vaccinating them against a wide range of nasty diseases, as well as raising money to support the invaluable work that the hospital does."
Allan Eves from Alder Hey Children’s Charity said: "We care for over 275,000 children, young people and their families treating everything from common illnesses to highly complex and specialist conditions. We also lead research into children’s medicines, infection, inflammation and oncology and our charity has raised over £22m to support Alder Hey Children’s Hospital, funding life-saving medical equipment, research and vital facilities. We are so pleased to be working with White Cross Vets on this superb fund-raising initiative and can’t wait to meet the vets and nurses who are helping us."
Sarah added: "We are aiming to raise £5,000, but it could be more. We also want to support the hospital’s therapy dog by providing them with our Complete Wellness Plan for free. The plan provides free health-checks, veterinary care and preventative treatment on an ongoing basis. We already give free membership to several Fire Service Search Dog Teams, as we feel it’s really important to look after these amazing dogs which dedicate their lives to help people."
The charitable campaign is running from the 4th September until the 31st December and plans are also in place for the veterinary surgeons and nurses from White Cross Vets to visit the hospital regularly to talk to the children about pets.
Sarah said: "We give every one of our team four paid donation days a year, so that they can volunteer with a charity of their choice, and we are keen to further our partnership with the hospital by visiting regularly. We already do this in numerous schools across the region and know just how much children love to find out about our day to day roles, and they always have plenty of interesting questions for our nurses and vets to answer."
The researchers’ objective was to determine whether dogs with intracranial space occupying lesions (iSOLs) on MRI, or MRI-determined indicators of intracranial hypertension (ICH) had higher sedation scores with a more rapid onset of recumbency after the administration of IV butorphanol than dogs without intracranial disease.
They hypothesised that 0.2 mg kg-1 of butorphanol administered intravenously would result in statistically significantly higher sedation scores and quicker onset of recumbency in dogs with MRI-iSOL and MRI-ICH.
For the observational study: 'The sedative effect of intravenous butorphanol in dogs with intracranial space occupying lesions or indicators of intracranial hypertension', 53 dogs presented for a brain MRI.
Each dog was sedated with 0.2 mg kg-1butorphanol IV, and the quality of sedation and the onset of recumbency were scored before drug administration and every 5 minutes after administration for 15 minutes using a modified sedation scale.
The maximum sedation score was 18, and onset of recumbency was recorded when a dog lay down without the ability to stand.
Dogs with MRI-iSOL had significantly higher median sedation scores than dogs without MRI-iSOL (12 versus 5 respectively) 15 minutes after butorphanol administration (T15, p < 0.01).
A greater number of dogs with MRI-ICH achieved recumbency (n = 9/10; 90%) than those without MRI-ICH (n = 20/43; 46.5%; p = 0.01).
Emma Sansby, Resident in Anaesthesia and Analgesia at Lumbry Park Veterinary Specialists, who led the research, said: “When intracranial disease is suspected, the administration of butorphanol as a premedicant for anaesthesia could be used to predict the presence of MRI-iSOL and MRI-ICH.
"If a dog becomes recumbent or has a sedation score of more than 10 within 15 minutes of butorphanol administration, the animal should be treated with an anaesthesia protocol adapted to the presence of ICH – so as not to increase intracranial pressure.
“These adaptations include but are not limited to; adequate preoxygenation - to prevent hypoxaemia and elevation of the head to no more than 30 degrees; preventing increases in central venous pressure - by avoiding jugular compression and avoiding excessive intraabdominal and intrathoracic pressure; and a smooth anaesthetic induction - ensuring an adequate depth of anaesthesia prior to tracheal intubation to prevent the cough reflex and judicious mechanical ventilation to enable a low-normal end-tidal carbon dioxide.”
Reference
Presented by Sam Taylor BVetMed(Hons) CertSAM DipECVIM-CA MANZCVS FRCVS, the webinar will also be available to watch on demand later, for those who miss it.
Sam is an Internal Medicine and Feline Specialist and current ISFM Academy lead.
She recently chaired and co-authored the ISFM guidelines on the management of the inappetent hospitalised cat.
The webinar, which counts for one hour’s CPD, will cover:
Sarah Musgrave, Brand Manager at Dechra, said: “Inappetence is a common reason cats present to veterinary practices and it can be caused by multiple conditions.
"Management needs to look beyond just treating the underlying disease as factors such as stress, nausea and pain can play a significant role.
"Untreated inappetence has a substantial negative effect on recovery from illness and surgery, makes medicating cats difficult and may even hasten euthanasia decisions.
"The ‘Feline pawsative about feline inappetence?’ webinar will help educate on feline weight loss, why intervention to improve nutrition is important and the practical steps to treating inappetence.”
https://thewebinarvet.com/webinars/feline-pawsative-about-feline-inappetence.
For this study, researchers in Argentina, Italy, Austria and Chile, set out to evaluate the efficacy of and adverse events from the administration of ACEIs to treat preclinical MMVD in dogs, via a systematic review of published evidence conducted according to the Cochrane Handbook for Systematic Reviews of Interventions.
Certainty of evidence was assessed using the GRADE (https://gradepro.org) approach.
The main finding in relation to dogs with preclinical MMVD and cardiomegaly was backed by a high certainty of evidence. The certainty of evidence in relation to the efficacy of ACEI administration in dogs without cardiomegaly was low.
Dr Pablo Donati, corresponding author for the paper, said: “In recent times, multiple clinical trials have provided fundamental information to veterinary cardiology.
"In the era of evidence-based medicine, systematic reviews and meta-analyses have emerged as a fundamental tool for clinical decision-making by gathering, appraising and summarizing the best available evidence.
"It is the hope of the authors that this systematic review and meta-analysis helps in the decision-making process for the treatment of preclinical myxomatous mitral disease with angiotensin-converting enzyme inhibitors in dogs.”
Nicola Di Girolamo, Editor of JSAP, added: “In line with other leading journals, the JSAP is prioritizing the publication of methodologically sound systematic reviews such as this one.
"However, our readers should be aware that the findings of systematic reviews should always be considered in light of their internal validity, i.e. the quality of the included studies, and their external validity, i.e. the generalizability of the included studied to the individual patient.”
Donati, P., Tarducci, A., Zanatta, R., Verdier, N., Belerenian, G., Cordero, I., Villalta, C., Franco, J. and Tarragona, L. (2022), Angiotensin-converting enzyme inhibitors in preclinical myxomatous mitral valve disease in dogs: systematic review and meta-analysis. J Small Anim Pract. https://doi.org/10.1111/jsap.13461
Enalees offers a variety of point-of-care isothermal PCR animal diagnostics tests for canine, feline and equine infectious diseases, including parvo, leptospirosis, babesiosis and borreliosis.
The company says its tests are highly specific and sensitive and can detect the presence of a virus, parasite or microbe at a very early stage, without the use of expensive and complex equipment, within 30 minutes.
Lauren Craig is the General Manager of the new subsidiary. She said: “I will be coordinating the launch of the UK subsidiary and working with veterinary professionals to deliver Enalees’ unique portfolio offering in diagnostic testing and in clinic rapid PCR tests.
“I am incredibly excited for the challenge ahead and looking forward to working with a fantastic team with an important mission in this key market.”
www.enalees.com
To achieve the accreditation, Dechra’s Digital Learning team’s educational content, processes and services were reviewed and benchmarked against key opinion indicators by an LPI consultant.
Dechra Academy was first established in the UK in 2010 and has since launched in over 20 additional countries across the world.
Last year, over 5,000 veterinary professionals in the UK completed over 9,000 courses and there is currently over 60 hours of free CPD content available across the company’s therapy areas including endocrinology, dermatology, analgesia and anaesthesia, nutrition, equine analgesia and anaesthesia and locomotion.
The company has just launched the first of two courses in its ‘Purffect Partner’ series, which focuses on identifying and treating unintended feline weight loss.
A further four case studies will be added in the coming months.
www.dechra.co.uk/academy.
The RCVS has introduced a new online recording system for graduates starting their Professional Development Phase (PDP).
The new PDP database sits as a module within the Professional Development Record (PDR), launched by the RCVS in April to help veterinary surgeons and veterinary nurses plan, evaluate and record their CPD.
Freda Andrews, RCVS Head of Education said: "Bringing the PDP into the new Professional Development Record shows clearly how this stage of a vet's development is part of the continuum of professional development that starts at university and continues for as long as they practise. We are also developing a system for students to record their practical and clinical experience whilst at university and, once this is complete next year, the PDR will become a complete record of professional lifelong learning."
Like the rest of the PDR, the new PDP module offers extra space for notes, and allows documents such as case reports and presentations to be uploaded and stored. Responding to feedback from users of the old PDP system, the new interface is designed to be more user friendly than the previous PDP database, and contains interactive help, guidance on PDP and an easier means of recording case numbers against the clinical skills lists. All new graduates from 2012 are able to sign up to use the new PDP site and, once their account is activated, they will also be able to use the CPD area to record any additional CPD they might undertake.
Graduates from previous years who are still undertaking their PDP using the old database may continue on the old system for the time being, although at some stage within the next year or so, the old site will need to be archived. Anyone who would prefer to use the new system instead should contact the PDP administrator at the RCVS to discussed transferring (pdp@rcvs.org.uk 020 7202 0736). As the skills lists have changed slightly, however, an automatic transfer of data from the old to the new isn't possible.
The PDP links the 'Day One' competences that veterinary surgeons have achieved when they graduate to the 'Year One' competences which they are expected to have achieved after about a year in practice. Each vet's progress through the PDP is supervised by a Postgraduate Dean, and its completion also requires sign-off from the veterinary surgeon's employer or mentor.
For more information, or to sign up to the PDP, visit www.rcvs.org.uk/pdp.
Zoetis has announced that following a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), the European Commission has approved Apoquel (oclacitinib tablet) in the European Union for the treatment of pruritus associated with allergic dermatitis and the treatment of clinical manifestations of atopic dermatitis in dogs at least 12 months of age.
Developed by Zoetis, Apoquel is the first Janus kinase (JAK) inhibitor approved for veterinary use. The company says it inhibits the function of a variety of allergic, itch and pro-inflammatory cytokines dependent on JAK enzyme activity and thus stops the cycle of itch and inflammation occurring in skin allergies.
Michael Stegemann, Senior Director Global Development Organisation at Zoetis said: "Apoquel is a targeted treatment that specifically inhibits JAK-dependent cytokines involved in allergic skin disease in dogs. Its rapid anti-pruritic effect along with its anti-inflammatory properties provide fast relief to dogs. Relief from itch and inflammation is maintained in dogs receiving long-term treatment with Apoquel. This exciting innovation molecule offers quick, effective, and sustained itch relief; improves skin lesions continuously and can be used safely short or long-term."
Zoetis says that in clinical trials, Apoquel demonstrated safety and efficacy for the treatment of itch and resulted in improved skin lesions in dogs diagnosed with a number of allergic skin diseases as well as atopic dermatitis and treated either short or long term. The decrease in itch scores was observed by pet owners as soon as 24 hours after administration, the first observation time point, and itch continued to decrease compared to baseline until the end of the study. Skin lesions scores assessed by veterinary surgeons were significantly improved after one week and continued to improve long term during the studies (4 months). In these studies, the most common side effects observed in dogs treated with Apoquel were vomiting and diarrhea. Other reported side effects included lethargy, decreased or lack of appetite, skin irritation or infection, and ear irritation or infection.
Apoquel will be a POM-V treatment. Apoquel tablets, dosed at 0.4 to 0.6 mg/kg, are administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy if medium to long term treatment is required, such as in dogs with seasonal skin allergy and atopic dermatitis.
Zoetis plans to make Apoquel available to veterinary surgeons in the European Union during 2014. Meantime, Zoetis says it will be working with vets on the new science and research findings around itch and canine allergic diseases. For more information, visit www.zoetis.com, www.itchcycle.com.
The RCVS has announced that it is to trial a new alternative dispute resolution scheme for users of veterinary services who have complaints which aren't serious enough to call into question a veterinary surgeon or nurse's fitness to practice.
The College says that although it is obliged to investigate all complaints, currently it can only deal with the most serious of complaints raised against a veterinary surgeon's or registered veterinary nurse's fitness to practise. This means that many of the 800 or so complaints received every year by the College's Professional Conduct Department are closed with no further action.
Nick Stace, RCVS Chief Executive Officer and Secretary, said: "It was clear from our consultations last year for the First Rate Regulator initiative that many animal owners who had made complaints were dissatisfied and frustrated with the fact that we were unable to take their, often very legitimate, concerns any further.
"It is for this reason that we decided to launch a trial in order to determine how we could develop an alternative scheme that, through conciliation, would try and resolve these disputes in a way that would be acceptable to both parties.
"Although this trial is small-scale we hope that it will provide the framework for a permanent ADR scheme which I believe would both increase consumer confidence in the profession and help maintain and preserve its reputation.
"We hope that the profession will actively support the trial, and any future scheme, as a way of resolving those intractable disputes which we know can hang over veterinary surgeons and practices and that they recognise that, ultimately, what is good for the consumer can be good for the profession."
The trial will be administered by the Ombudsman Services, an independent and not-for-profit complaint resolution service, and limited to no more than 150 concerns raised about veterinary surgeons in regards to the treatment of a small animal. In most cases concerns referred to the trial will have no arguable case for serious professional misconduct. The trial is free to the users and voluntary, and consent will be sought from both parties before the concern is referred to the Ombudsman Services. The costs of the trial will not exceed £120,000.
Recommendations will be determined through conciliation between both parties and the Ombudsman Services will only be able to suggest, rather than impose, a solution that each party is entitled to accept, or not. Solutions could include, for example, financial accommodation up to the small claims court limit of £10,000 (although the average recommendation is around £100), the issuing of an apology or other practical action to remedy the situation.
The Ombudsman Services will be assisted in its investigations by veterinary advisers who will provide guidance on clinical and other veterinary matters.
The results of the trial, which will end in May 2015, will be presented at the June 2015 meeting of RCVS Council where steps will be considered for the development of a permanent scheme.
More details about the trial can be found at www.rcvs.org.uk/adr
MSD Animal Health (Merck in the US and Canada), has launched Finadyne (flunixin), the NSAID for cattle, as a pour on.
According to the company, Finadyne Transdermal is the world's first non-parasiticide cattle product to be made available as a pour-on.
Dr. Martin Behr, technical manager at MSD Animal Health said: “Finadyne Transdermal is uniquely designed for rapid absorption into the bloodstream and its antipyretic effect has been demonstrated as early as two hours after treatment. This is because innovative penetration enhancers are included in the formulation to improve the absorption of the active ingredient flunixin through the skin.”
The new product comes in pre-calibrated packaging and uses a bottle designed for easy application along an animal’s back.
Dr. Behr added: “It’s much simpler for farmers to treat cattle in this way – as opposed to administering an injection, which can also mean needle-site lesions that can reduce the value of a carcass or compromise hide quality.
“The time taken to handle and treat animals will be much reduced with a transdermal NSAID. There will also be a saving on syringes and needles.”
Finadyne Transdermal (POM-V) is available now from veterinary wholesalers. Further information is available from the MSD Animal Health veterinary support group on 01908 685685.
Mark Colonnese, Aquarium’s Sales and Marketing Director said: "As someone who owns two dogs, the results of the survey have not come as too much of a surprise to me, but I know that some of my colleagues were pretty surprised just how important we think our pets are."
The survey showed that the feelings were even stronger among women, 71% of whom would regard a pet death as equally upsetting to that of a family member’s, compared to 55% of men.
Mark added: "Our results really highlight the sensitivity of issues surrounding a pet’s death. While this would be obvious to, for instance, a life insurance company, our survey reinforces the need for an empathetic customer journey among pet insurers. The first step of this process is ensuring a smooth, seamless process to minimise stress for newly bereaved pet parents."
“Tilts, Spins, and Tears: Approaches to head tilts in rabbits” will be presented by Dr Madonna Livingstone BVMS MRCVS, who will discuss a range of approaches, diagnostic and treatment options for rabbits presenting with head tilt symptoms.
Madonna has over 20 years experience in veterinary practice, and as Head Vet and Head of Exotics at Ark Veterinary Clinics Ltd, she speaks widely on exotic animal medicine and surgery.
She also delivers clinical exotic lectures and practicals at Glasgow Vet School, holds a diploma in parrot behaviour and is publishing a textbook on rabbits and small exotic mammals this year.
The webinar aims to help veterinary staff to recognise the differential diagnosis list, know how to achieve a diagnosis, or most likely diagnosis within a restricted budget; know the available treatment options; and know how to manage owners’ expectations.
https://horiba.link/head-tilts-in-rabbits
Petplan has announced the finalists for the 2011 Petplan Veterinary Awards.
Now in its 12th year, the Petplan Veterinary Awards received its biggest response yet with over 2,800 nominations submitted for exceptional veterinary staff all over the UK.
The finalists for each of the categories are as follows:
Vet of the YearCharles Bagnal, Orwell Veterinary Group - Ipswich Alison Laurie, Crown Vets - Highlands Daniel Parry, Village Vet Garden Suburb - London
Vet Nurse of the YearEmma Clare, Copthorne Veterinary Clinic - Shropshire Maria Corcoran, Orwell Veterinary Group - Ipswich Ingrid Hunt, Cranbrook Veterinary Centre - Devon
Support Staff of the YearBev Millward, Milton Keynes Veterinary Group - Milton KeynesLauren Hunter, The Ferns Veterinary Practice - Dunkeld Patty Fraser, Loch Leven Equine Practice - Kinross
Vet Practice of the YearAshfield House Veterinary Hospital Ltd - Nottinghamshire Emersons Green Veterinary Surgery Ltd - Avon Leonard Brothers Veterinary Centre Ltd - Shropshire
Alison Andrew, Petplan's Marketing Manager, said: "The nominations get bigger and better every year and we're absolutely delighted to announce the finalists for 2011. With 70% of veterinary practices within 3 miles of their patients, veterinary staff are an important part of the community and that's why we feel it important that they have a chance to receive the recognition they deserve. We're looking forward to revealing the winners on 31st of March."
All finalists will be invited to an elegant awards ceremony that will take place on 31st March at the Birmingham Town Hall, where the winners will be announced.
For further information, visit http://www.petplanvet.co.uk/
Vétoquinol has launched Flexadin, a new range of joint support products for cats and dogs with osteoarthritis (OA)
Robert Simpson, Flexadin Product Manager said: "This new range is made up of two products: Flexadin Plus and Flexadin Advanced, both are dietetic complementary feeds which are members of a small group of joint support products which contain Omega-3 fatty acids and Vitamin E. These ingredients are proven to aid the support of the metabolism of joints in the case of OA. Although many different joint support aids are available, not all of them contain these extra ingredients."
Vétoquinol says that in addition to Omega-3 fatty acids and Vitamin E, Flexadin Plus contains the traditional ingredients: glucosamine, chondroitin and devil's claw. Flexadin Advanced contains the novel ingredient, UCII - a type of undenatured type II collagen which has been manufactured using a patented process.
Flexadin Plus comes in two formulations, the first is specifically designed for cats/small dogs and the other is for medium/large dogs. Flexadin Advanced is specifically for dogs.
Robert added: "Flexadin Advanced has a specific property which means that the administration rate is only one chew per day whatever the weight of the dog. This has an important impact on the price per day for medium and large dogs which may require more than one tablet of traditional joint support products. This property also makes Flexadin Advanced a convenient option for owners. In addition to this benefit, UCII is becoming more and more popular due to the results of scientific studies in dogs, horses and even humans.
"We are all very excited about the advances this range can bring to veterinary practices."
Both Flexadin Plus and Advanced are presented as palatable, shaped, soft chews which come in zip-lock packs to keep the soft chews fresh and tasty. Flexadin Plus comes in packs of 90 chews whilst Flexadin Advanced comes in packs of 30 chews.
For further information about Flexadin, contact Vétoquinol on: 01280 825424.